S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
The Dodgers gave Shohei Ohtani $700 million to hit and pitch — but also because he can sell
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology (Ad)
Elon Musk restores X account of conspiracy theorist Alex Jones
At UN climate talks, cameras are everywhere. Many belong to Emirati company with a murky history
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology (Ad)
The EU wants to put a tax on emissions from imports. It's irked some other nations at COP28
Miyazaki's 'The Boy and the Heron' is No. 1 at the box office, a first for the Japanese anime master
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology (Ad)
AP PHOTOS: Moscow hosts a fashion forum with designers from Brazil, China, India and South Africa
Military-themed brewery wants to open in a big Navy town. An ex-SEAL is getting in the way
S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
The Dodgers gave Shohei Ohtani $700 million to hit and pitch — but also because he can sell
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology (Ad)
Elon Musk restores X account of conspiracy theorist Alex Jones
At UN climate talks, cameras are everywhere. Many belong to Emirati company with a murky history
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology (Ad)
The EU wants to put a tax on emissions from imports. It's irked some other nations at COP28
Miyazaki's 'The Boy and the Heron' is No. 1 at the box office, a first for the Japanese anime master
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology (Ad)
AP PHOTOS: Moscow hosts a fashion forum with designers from Brazil, China, India and South Africa
Military-themed brewery wants to open in a big Navy town. An ex-SEAL is getting in the way
S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
The Dodgers gave Shohei Ohtani $700 million to hit and pitch — but also because he can sell
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology (Ad)
Elon Musk restores X account of conspiracy theorist Alex Jones
At UN climate talks, cameras are everywhere. Many belong to Emirati company with a murky history
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology (Ad)
The EU wants to put a tax on emissions from imports. It's irked some other nations at COP28
Miyazaki's 'The Boy and the Heron' is No. 1 at the box office, a first for the Japanese anime master
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology (Ad)
AP PHOTOS: Moscow hosts a fashion forum with designers from Brazil, China, India and South Africa
Military-themed brewery wants to open in a big Navy town. An ex-SEAL is getting in the way
S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
The Dodgers gave Shohei Ohtani $700 million to hit and pitch — but also because he can sell
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology (Ad)
Elon Musk restores X account of conspiracy theorist Alex Jones
At UN climate talks, cameras are everywhere. Many belong to Emirati company with a murky history
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology (Ad)
The EU wants to put a tax on emissions from imports. It's irked some other nations at COP28
Miyazaki's 'The Boy and the Heron' is No. 1 at the box office, a first for the Japanese anime master
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology (Ad)
AP PHOTOS: Moscow hosts a fashion forum with designers from Brazil, China, India and South Africa
Military-themed brewery wants to open in a big Navy town. An ex-SEAL is getting in the way

bluebird bio (BLUE) News Today

$2.86
-1.95 (-40.54%)
(As of 12/8/2023 ET)
Compare
Today's Range
$2.69
$5.53
50-Day Range
$2.61
$4.83
52-Week Range
$2.52
$8.52
Volume
54.13 million shs
Average Volume
4.24 million shs
Market Capitalization
$312.71 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$8.02
SourceHeadline
finance.yahoo.com logoLong-Term Data Presented at ASH Support beti-cel as a Potentially Curative Gene Therapy for β-Thalassemia Patients Who Require Regular Transfusions Through Achievement of Durable Transfusion Independence and Normal or Near-Normal Adult Hb Levels
finance.yahoo.com - December 10 at 1:05 PM
businesswire.com logoLong-term Follow-up Data From bluebird’s Gene Therapy Program in Sickle Cell Disease Support Durable, Potentially Curative Benefits Through Stable Production of Anti-Sickling ...
businesswire.com - December 9 at 3:24 PM
finance.yahoo.com logoLong-term Follow-up Data From bluebird’s Gene Therapy Program in Sickle Cell Disease Support Durable, Potentially Curative Benefits Through Stable Production of Anti-Sickling Adult Hemoglobin and Resolution of Vaso-Occlusive Events
finance.yahoo.com - December 9 at 3:24 PM
markets.businessinsider.com logoBluebird Bio’s Hold Rating Maintained Amid Launch Challenges and Market Competition
markets.businessinsider.com - December 9 at 10:24 AM
MarketBeat logobluebird bio (NASDAQ:BLUE) Upgraded by Morgan Stanley to "Equal Weight"
americanbankingnews.com - December 9 at 5:05 AM
MarketBeat logobluebird bio (NASDAQ:BLUE) Upgraded to "Sell" by StockNews.com
americanbankingnews.com - December 9 at 4:27 AM
MarketBeat logoEquities Analysts Offer Predictions for bluebird bio, Inc.'s FY2024 Earnings (NASDAQ:BLUE)
americanbankingnews.com - December 9 at 2:28 AM
marketwatch.com logoBluebird Bio Shares Slide 41% on Black-Box Label, Higher Price for Sickle-Cell Treatment
marketwatch.com - December 8 at 5:42 PM
msn.com logoMidday movers: Lululemon, Paramount and more
msn.com - December 8 at 5:42 PM
marketbeat.com logo
marketbeat.com - December 8 at 1:55 PM
marketbeat.com logo
marketbeat.com - December 8 at 1:51 PM
marketbeat.com logo
marketbeat.com - December 8 at 1:41 PM
marketbeat.com logo
marketbeat.com - December 8 at 1:33 PM
msn.com logoMorgan Stanley ups bluebird to equal weight ahead of FDA decision
msn.com - December 8 at 12:42 PM
finance.yahoo.com logoFDA Approves World’s First Crispr Gene-Editing Drug for Sickle-Cell Disease
finance.yahoo.com - December 8 at 12:42 PM
marketbeat.com logo
marketbeat.com - December 8 at 11:24 AM
finance.yahoo.com logobluebird bio (BLUE) Stock Gains 25.6% in a Month: Here's How
finance.yahoo.com - December 1 at 12:58 PM
seekingalpha.com logobluebird bio Isn't Priced For Success
seekingalpha.com - December 1 at 1:27 AM
seekingalpha.com logoBuy bluebird bio's Lovo-Cel As It Transforms Sickle Cell Disease Treatment
seekingalpha.com - November 29 at 9:57 PM
msn.com logoSkysona: The gene therapy that saved Darius’ life cannot help any more European children
msn.com - November 25 at 10:41 PM
markets.businessinsider.com logoReassessing Bluebird Bio: Inflation Concerns Overblown, Underperformance Unjustified, and Growth Potential Undervalued
markets.businessinsider.com - November 20 at 7:56 PM
finance.yahoo.com logoHere's Why bluebird bio (NASDAQ:BLUE) Must Use Its Cash Wisely
finance.yahoo.com - November 14 at 10:33 AM
markets.businessinsider.com logoAnalysts Have Conflicting Sentiments on These Healthcare Companies: Doximity (DOCS), Arbutus Biopharma (ABUS) and Bluebird Bio (BLUE)
markets.businessinsider.com - November 10 at 8:15 PM
markets.businessinsider.com logoAnalysts Offer Insights on Healthcare Companies: Arvinas Holding Company (ARVN), Bluebird Bio (BLUE) and Marinus (MRNS)
markets.businessinsider.com - November 10 at 8:15 PM
markets.businessinsider.com logoHold Rating on Bluebird Bio: Assessing Financial Position, Future Prospects, and Product Launches
markets.businessinsider.com - November 8 at 8:01 PM
finance.yahoo.com logobluebird bio, Inc. (NASDAQ:BLUE) Q3 2023 Earnings Call Transcript
finance.yahoo.com - November 8 at 8:01 PM
markets.businessinsider.com logoAnalysts Offer Insights on Healthcare Companies: Bluebird Bio (BLUE) and Marinus (MRNS)
markets.businessinsider.com - November 8 at 9:59 AM
msn.com logoBluebird Bio To Rally Around 267%? Here Are 10 Top Analyst Forecasts For Wednesday
msn.com - November 8 at 9:59 AM
finance.yahoo.com logoWhy Bluebird Bio Stock Soared 7% Higher on Tuesday
finance.yahoo.com - November 7 at 7:10 PM
finance.yahoo.com logobluebird (BLUE) Q3 Earnings Top; Zynteglo, Skysona Fuel Sales
finance.yahoo.com - November 7 at 2:09 PM
markets.businessinsider.com logoHere's what Wall Street expects from bluebird bio's earnings report
markets.businessinsider.com - November 7 at 9:09 AM
msn.com logobluebird bio GAAP EPS of -$0.66 beats by $0.01, revenue of $12.39M misses by $1.02M
msn.com - November 7 at 9:09 AM
markets.businessinsider.com logoBluebird Bio Q3 Loss Narrows, Tops Estimates; Revenues Miss Estimates
markets.businessinsider.com - November 7 at 9:09 AM
finance.yahoo.com logobluebird bio Reports Third Quarter 2023 Financial Results and Highlights Operational Progress
finance.yahoo.com - November 7 at 9:09 AM
finance.yahoo.com logoBluebird Bio Inc (BLUE) Reports Q3 2023 Financial Results: Strong Commercial Launch and ...
finance.yahoo.com - November 7 at 9:09 AM
msn.com logobluebird bio Q3 2023 Earnings Preview
msn.com - November 6 at 10:49 PM
markets.businessinsider.com logoHold Rating Retained for Bluebird Bio Amid Potential PRV Sale and Market Factors
markets.businessinsider.com - November 2 at 11:22 PM
finance.yahoo.com logobluebird bio to Present New and Updated Data from Gene Therapy Programs in Sickle Cell Disease and Beta-Thalassemia at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition
finance.yahoo.com - November 2 at 1:18 PM
markets.businessinsider.com logoSensei Biotherapeutics Appoints Stephanie Krebs, MS, MBA, as Chief Business Officer
markets.businessinsider.com - November 1 at 10:11 AM
nytimes.com logoPanel Says That Innovative Sickle Cell Cure Is Safe Enough for Patients
nytimes.com - October 31 at 6:20 PM
msn.com logoBluebid bio to sell FDA voucher for $103M if sickle cell disease therapy approved
msn.com - October 31 at 1:19 PM
msn.com logoCure for sickle cell disease on the horizon? US drug regulator is reviewing 2 new gene therapies
msn.com - October 31 at 1:19 PM
finance.yahoo.com logoBluebird Bio (BLUE) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
finance.yahoo.com - October 31 at 1:19 PM
finance.yahoo.com logoUPDATE 1-Bluebird bio to sell sickle cell FDA voucher for $103 mln if therapy approved
finance.yahoo.com - October 30 at 9:21 AM
reuters.com logoBluebird bio to sell sickle cell gene therapy FDA voucher for $103 million if approved
reuters.com - October 30 at 9:21 AM
finance.yahoo.com logobluebird bio Enters into Advance Agreement to Sell Priority Review Voucher, if Granted, for $103 Million
finance.yahoo.com - October 30 at 9:21 AM
msn.com logoBluebird stock falls 10% ahead of FDA meeting for rival sickle cell therapy
msn.com - October 27 at 6:13 PM
thestreet.com logoBluebird Bio Stock Soars After Company Details Promising Cancer Treatment
thestreet.com - October 25 at 10:42 AM
finance.yahoo.com logobluebird bio to Host Third Quarter 2023 Financial Results Conference Call
finance.yahoo.com - October 24 at 12:35 PM
finance.yahoo.com logoA Look At The Fair Value Of bluebird bio, Inc. (NASDAQ:BLUE)
finance.yahoo.com - October 18 at 7:43 AM
Get bluebird bio News Delivered to You Automatically

Sign up to receive the latest news and ratings for BLUE and its competitors with MarketBeat's FREE daily newsletter.



BLUE Media Mentions By Week

BLUE Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

BLUE
News Sentiment

0.50

0.52

Average
Medical
News Sentiment

BLUE News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

BLUE Articles
This Week

22

4

BLUE Articles
Average Week

Get bluebird bio News Delivered to You Automatically

Sign up to receive the latest news and ratings for BLUE and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools

This page (NASDAQ:BLUE) was last updated on 12/10/2023 by MarketBeat.com Staff

My Account -